Olor de pies

1-Deoxynojirimycin (DNJ), isolated from mulberry (Morus alba) leaves, is a potent alpha-glucosidase inhibitor that reduces postprandial glucose spikes and has been shown to enhance insulin sensitivity. A human RCT with 84 healthy adults confirmed DNJ reduces postprandial blood glucose and insulin responses. A 12-week placebo-controlled RCT in 76 subjects with impaired glucose metabolism showed improved long-term glycemic control.

In an aging mouse model, 2'-FL significantly relieved glucose intolerance as part of broader metabolic disorder amelioration, linked to modulation of the gut microbiome-T cell axis and restoration of CD4+ T-helper cells known to correlate with insulin sensitivity. A randomized, double-blind human trial in overweight/obese adults measured insulin sensitivity after 8 weeks of 2'-FL supplementation, but observed only limited metabolic effects. The evidence is primarily preclinical, with human trials yielding modest or non-significant results for insulin-related endpoints.

4-Hydroxyisoleucine is an unusual amino acid isolated from fenugreek seeds (Trigonella foenum-graecum) that directly increases glucose-dependent insulin secretion from beta cells and improves insulin sensitivity by activating AMPK in skeletal muscle. Studies show it reverses TNF-α-induced insulin resistance and improves blood lipid and glucose profiles in diabetic animal models.

5-Aminoimidazole-4-Carboxamide Ribonucleotide (AICAR), the cell-permeable precursor to AICA riboside (acadesine), directly activates AMPK, stimulating skeletal muscle glucose uptake independent of insulin. Human studies confirm AICAR infusion acutely improves glucose disposal, making it a direct insulin sensitivity tool in research and clinical contexts.

ALC is a mitochondrial carrier involved in glucose and lipid metabolism, and clinical data show it can improve insulin sensitivity in insulin-resistant, non-diabetic subjects. A pilot RCT demonstrated increased glucose disposal rate and improved glucose tolerance after 6 months of ALC (2 g/day). However, a larger subsequent RCT in type 2 diabetic patients on statin therapy did not replicate these benefits, suggesting effects may be population-dependent.

Multiple rodent studies demonstrate that adzuki bean supplementation improves insulin sensitivity by reducing HOMA-IR, lowering fasting insulin, and activating IRS-1/AKT signaling. In vitro work shows adzuki bean peptides increase IRS-1, Akt-1, and GLUT2 protein expression in human liver cells. Limited human data exist but support biological plausibility.

The Maeda et al. (2005) RCT demonstrated that HOMA-IR (homeostatic model assessment of insulin resistance) decreased significantly in both groups, with the insulin area under the curve after OGTT declining significantly in the agar group specifically. Postprandial insulin levels decreased more significantly in the agar group than in controls, suggesting improved insulin sensitivity.

The most robustly documented human clinical outcome for A. muciniphila is improved insulin sensitivity. In a double-blind RCT, pasteurized A. muciniphila at 10¹⁰ cells/day for 3 months produced a statistically significant 28.6% improvement in insulin sensitivity and a ~34% reduction in plasma insulin versus placebo. Mechanistically, A. muciniphila reduces endotoxin penetration, decreases systemic inflammation, and stimulates incretin (GLP-1) secretion, all of which contribute to insulin sensitisation.

ALA activates PPARγ and modulates adiponectin signaling, improving insulin sensitivity in preclinical and some clinical settings. Human RCT evidence on glycemic control markers is mixed, with some studies showing improved insulin sensitivity while meta-analyses show no consistent effect on HbA1c or fasting glucose.

Alpha-lipoic acid (ALA) is a natural antioxidant compound with well-documented effects on insulin sensitivity, prescribed in conditions including diabetic polyneuropathy, metabolic syndrome, PCOS, and obesity. Short-term oral ALA treatment has been shown to increase peripheral insulin sensitivity in T2DM patients. It works through AMPK activation, promotion of glucose cellular uptake, and antioxidant mechanisms.

The evidence for almonds improving insulin sensitivity is mixed. Several RCTs, particularly in South Asian and pre-diabetic populations, show reductions in fasting insulin, HOMA-IR, and HbA1c. However, a rigorous crossover RCT found that adding almonds to an existing diet without substitution worsened insulin sensitivity in overweight/obese adults with prediabetes, likely due to weight gain.

A systematic meta-analysis of five RCTs in 415 pre-diabetic and early diabetic patients showed aloe vera significantly reduced fasting blood glucose (WMD: −30.05 mg/dL) and HbA1c (WMD: −0.41%). Proposed mechanisms include increased insulin sensitivity in peripheral cells and enhancement of pancreatic beta-cell insulin genetics activity.

Galangin from A. galanga rhizome reduced plasma insulin levels and improved insulin sensitivity in fructose-fed Wistar rat models. Multiple diabetic animal studies show restored lipid and glucose parameters consistent with improved insulin sensitivity. Human evidence is not yet available.

AMPK is a key intracellular energy sensor and master regulator of glucose metabolism. Its activation stimulates glucose uptake via GLUT4 translocation, increases fat oxidation, improves mitochondrial function, and suppresses hepatic gluconeogenesis—all mechanisms that improve insulin sensitivity. It is a recognized pharmacological target for insulin resistance and T2DM.

Higher omega-3 index from marine sources including anchovies is associated with improved insulin sensitivity. A cross-sectional study found insulin sensitivity was 43% higher in men with high vs. low omega-3 index, and a 2024 meta-analysis confirmed marine omega-3s may exert insulin-sensitizing effects through anti-inflammatory and triglyceride-lowering mechanisms.

Andrographis paniculata and its primary diterpene andrographolide have demonstrated anti-hyperglycemic and insulin-sensitizing effects in animal studies and limited clinical evidence. Andrographolide activates PPAR-γ and AMPK pathways, improves GLUT4 expression, and reduces hepatic gluconeogenesis. Traditional Ayurvedic and Thai medicinal use for metabolic conditions is documented.

Andrographolide is the primary bioactive diterpene from Andrographis paniculata with demonstrated insulin-sensitizing properties in cell and animal models. It activates PPAR-γ and AMPK, enhances GLUT4 translocation, and reduces hepatic gluconeogenesis. Traditional Ayurvedic use of the parent plant for diabetes is well-documented.

Mangiferin, a key xanthone in anemarrhena, has been shown in animal models to reduce insulin resistance and improve insulin sensitivity in type-2 diabetic subjects. Sarsasapogenin also demonstrates antidiabetic and anti-osteoclastogenic properties. Multiple mechanisms including GLP-1 secretion stimulation have been identified.

Annatto delta-tocotrienol reduced HOMA-IR by 13.1% in a 24-week RCT of 110 T2DM patients. A separate RCT in metabolic syndrome subjects and animal data from Texas Tech University confirm improvements in insulin sensitivity. The proposed mechanism involves reduced oxidative stress and inflammation in insulin-signaling pathways.

Apple phloridzin inhibits intestinal SGLT-1 and renal SGLT-2 glucose transporters, reducing glucose absorption and reabsorption. RCT meta-analysis data suggest a trend toward insulin sensitivity improvement with apple intake, particularly in serum-based measurements.

Clinical trials show ACV can improve markers of insulin sensitivity, including HOMA-IR and QUICKI, particularly in individuals with type 2 diabetes or insulin resistance. Acetic acid is thought to activate AMPK and reduce hepatic glucose output. Results are modest and heterogeneous across studies.

L-arginine improves insulin sensitivity via NO-mediated enhancement of glucose transporter activity, and several preclinical and clinical studies support this in obese and type 2 diabetic patients. The AKG moiety independently reduces plasma glucose, triacylglycerols, and BCAA concentrations through distinct metabolic pathways.

Aronia melanocarpa has been shown in animal models and mechanistic studies to improve insulin sensitivity by inhibiting DPP-IV and α-glucosidase, stimulating hepatic glycogen synthesis, and attenuating insulin resistance. Clinical data show reductions in postprandial glucose and blood glucose in diabetic patients, and one rat model demonstrated reduced insulin concentration after standardized extract supplementation.

A meta-analysis of nine RCTs demonstrated that artichoke supplementation significantly reduced HOMA-IR (WMD: −0.52, p=0.002) in a subgroup using artichoke alone. Chlorogenic acid modulates gluconeogenic enzymes and luteolin supports insulin receptor signaling. A 2024 RCT also showed improved insulin sensitivity markers with artichoke/bergamot combination.

Ashitaba chalcones improve insulin sensitivity in animal models via AMPK activation, PTP1B inhibition, and α-glucosidase inhibition. A human metabolic syndrome pilot confirmed antidiabetic activity. XA and 4-HD reduce HOMA-IR (insulin resistance index) in fructose-fed rat models.

Ashwagandha improves insulin sensitivity through multiple mechanisms including AMPK activation, PPAR-γ modulation, and inhibition of DPP-4. Clinical studies in diabetic and overweight populations have observed improvements in insulin resistance markers. A 2025 PMC review specifically addressing insulin resistance confirmed supportive preclinical and clinical evidence.

Asparagus officinalis extract has been shown to improve insulin secretion and beta-cell function in animal models of type 2 diabetes. A human open trial showed significant reduction in fasting plasma glucose after asparagus powder consumption. Mechanisms include alpha-glucosidase inhibitory activity and direct pancreatic beta-cell stimulation.

ASX reduces insulin resistance measured by HOMA-IR across multiple human RCTs, with the strongest effects observed at the hepatic level. In PCOS patients (n=58, 12 mg/day, 8 weeks), it significantly reduced HOMA-IR and fasting insulin. Mechanistically, it enhances antioxidant capacity (SOD, TAC) and lowers oxidative markers that disrupt insulin signaling.

Astragalus saponins and polysaccharides activate the AMPK–adiponectin axis in liver and skeletal muscle, increasing insulin sensitivity. Clinical research in T2DM patients confirms PPAR-gamma upregulation, associated with reduced insulin resistance. A 2024 meta-analysis showed significant reductions in fasting glucose and HbA1c when added to metformin.

AMR polysaccharides improve insulin sensitivity in type 2 diabetic animal models by reducing plasma insulin, increasing insulin sensitivity index, and activating PI3K/Akt signalling. Preclinical work consistently supports this mechanism, and a clinical formula-level study in obese T2DM patients showed metabolic improvement.

Banaba (Lagerstroemia speciosa) leaf extract, standardized for corosolic acid and ellagitannins, improves cellular glucose absorption, reduces gluconeogenesis, boosts glucokinase activity, and enhances insulin sensitivity. A 12-week placebo-controlled RCT in prediabetics demonstrated significant reductions in HbA1c, fasting plasma glucose, and HOMA-IR.

Native banana starch supplementation significantly improved insulin sensitivity in obese type 2 diabetic women (24 g/day, 4 weeks RCT) and in non-diabetic obese women (30 g/day, 8 weeks). The mechanism involves resistant starch slowing glucose absorption, reducing postprandial insulin demand, and promoting favorable gut microbiome changes. Green banana products were identified as a key area of study in the 2019 systematic review specifically for glycemic/insulin metabolism benefits.

A small human study reported that adding baobab to white bread reduced the amount of insulin needed to transport blood glucose to tissues, suggesting improved insulin sensitivity. The mechanism involves polyphenol-mediated inhibition of carbohydrate-digesting enzymes and fiber-driven slowing of glucose absorption. A published RCT (MDPI 2022) also found significantly lower peak glucose concentration following baobab consumption compared with control, consistent with improved insulin dynamics.

Berberine from barberry improves insulin sensitivity by activating AMPK, increasing insulin receptor expression, and reducing insulin resistance markers (HOMA-IR). Clinical trials in T2DM and metabolic syndrome patients confirm reductions in fasting insulin and HOMA-IR. Berberine's efficacy is comparable to metformin in some measures.

Barley β-glucan has been evaluated in RCTs for its effects on insulin sensitivity in at-risk individuals. A 12-week double-blind RCT found dose-dependent trends toward improved insulin metabolism in pre-diabetic adults consuming reduced-viscosity barley β-glucan. Effects appear most consistent in individuals with existing metabolic risk.

A 2018 meta-analysis of holy basil RCTs found significant reductions in HOMA-IR (from 3.61 to 2.41), indicating improved insulin sensitivity. Active compounds eugenol and ursolic acid enhance insulin receptor signaling and glucose transport. A 2024 RCT (n=200) also reported improved glycemic control markers consistent with enhanced insulin sensitivity.

Beetroot nitrate and betalains have demonstrated improvements in insulin sensitivity across small RCTs in obese and diabetic populations. Nitrate-derived NO augments glucose uptake in skeletal muscle, while betalains reduce oxidative stress that impairs insulin signaling.

A clinical study in 40 patients with type 2 diabetes and cardiac autonomic neuropathy found that benfotiamine treatment reduced insulin resistance markers (immunoreactive insulin, HOMA) alongside inflammatory cytokines. Mechanistically, benfotiamine activates transketolase and may enhance insulin synthesis in insulin-producing cells under high-glucose conditions.

Berberine activates AMPK to improve insulin sensitivity and reduce insulin resistance, with multiple RCTs and meta-analyses in patients with metabolic syndrome and type 2 diabetes demonstrating significant reductions in HOMA-IR. A 2021 systematic review and meta-analysis of RCTs confirmed blood sugar-lowering and insulin resistance amelioration, with effects becoming more pronounced after more than 3 months of treatment. Clinical studies show reduced HOMA-IR and improved adipokine profiles in metabolic syndrome patients after 3 months of treatment.

Berberis species (including B. vulgaris and B. aquifolium) are the primary plant sources of berberine, the well-documented insulin-sensitizing alkaloid. Berberine from Berberis activates AMPK, reduces insulin resistance, and lowers HOMA-IR in multiple RCTs. Traditional use in Ayurveda and TCM for metabolic and digestive disorders predates modern evidence.

Meta-analytic evidence from human RCTs shows that carnosine or BA supplementation reduces HOMA-IR (a marker of insulin resistance) and fasting insulin, suggesting improved insulin sensitivity in people with impaired glucose metabolism. The 2021 Advances in Nutrition meta-analysis found a reduction in HOMA-IR (SMD: −0.41) and fasting insulin (SMD: −0.41) in humans. Mechanistic pathways involve anti-glycation, reduction of oxidative stress in insulin-sensitive tissues, and GLUT4 upregulation.

Beta-glucan consistently reduces postprandial glucose and insulin responses, and clinical meta-analyses in type 2 diabetic patients confirm reductions in fasting glucose and HbA1c at 3 g/day. However, direct improvements in fasting insulin sensitivity (as measured by insulin concentrations or HOMA-IR) have not been consistently demonstrated in diabetic meta-analyses, with the primary effect being glucose absorption modulation.

Plasma betaine levels are approximately 14% lower in insulin-resistant versus insulin-sensitive individuals, and lower betaine is associated with a 16% lower hazard for incident T2D per SD increase in the Diabetes Prevention Program cohort. A 12-week RCT in 27 obese prediabetic participants found betaine reduced insulin AUC on OGTT (p=0.038) but did not improve insulin sensitivity by euglycemic clamp. Animal models robustly show betaine improves insulin tolerance and glucose homeostasis.

B. breve strains have shown benefits for insulin metabolism in clinical RCTs. A double-blind RCT in 101 obese children and adolescents with insulin resistance found that B. breve BR03 and B632 supplementation produced beneficial effects on insulin metabolism. A 12-week RCT in T2DM patients showed B. breve supplementation significantly reduced HbA1c compared to placebo.

B. lactis TISTR 2591 improved HOMA-IR and enhanced β-cell function (HOMA-β) in a crossover RCT of T2DM patients. The proposed mechanism involves SCFA production, reduced gut permeability, and modulation of the inflammatory milieu that underlies insulin resistance.

Bilberry anthocyanins activate AMPK in key insulin-sensitive tissues (adipose, muscle, liver), upregulate GLUT4, and suppress hepatic glucose output in animal models. Human clinical data include a crossover trial showing reduced postprandial glucose and insulin in T2DM. Long-term HbA1c improvements have been reported in systematic review data for certain populations.

Bile acids enhance insulin sensitivity via FXR activation of hepatic insulin-AKT signaling, TGR5-stimulated GLP-1 release improving peripheral insulin action, and suppression of hepatic gluconeogenesis. Bile acid sequestrant administration in human patients has been demonstrated to increase insulin sensitivity, and UDCA has been shown to improve insulin sensitivity in clinical studies. Bariatric-surgery-induced bile acid elevation correlates with improved insulin sensitivity.

RCTs and meta-analyses confirm N. sativa reduces insulin resistance (HOMA-IR) and improves β-cell function. A one-year trial showed significantly lower insulin resistance and higher β-cell activity. Subgroup analysis found HOMA-IR decreased with >1 g/day N. sativa for >8 weeks.

Multiple mechanisms—AMPK activation, GLUT4 upregulation, and anti-inflammatory actions reducing metabolic inflammation—underpin piperine's insulin-sensitizing effects. Animal studies consistently show improved insulin tolerance, and human data (largely via curcumin-piperine RCTs) report reduced HOMA-IR. Direct piperine-only human evidence remains sparse.

A key RCT using a gold-standard hyperinsulinemic-euglycemic clamp demonstrated significant improvement in whole-body insulin sensitivity in obese, insulin-resistant adults given blueberry bioactives for 6 weeks. Subsequent larger trials have shown inconsistent results.

A Journals of SAGEPUB review (Nielsen & Meacham, 2011) states that 'limited evidence suggests that boron can facilitate insulin action.' Mechanistically, boron may influence thyroid hormone conversion (T4→T3), which in turn affects insulin sensitivity; animal and limited human data support this pathway.

LBPs improve insulin sensitivity by modulating hepatic lipid and glucose metabolism genes and enhancing oral glucose tolerance in diabetic animal models. Human trial data show increased insulinogenic index with LBP supplementation. Mechanistic studies point to suppression of SREBP-1c and FAS as key pathways.

Multiple human RCTs demonstrate that broccoli sprout powder and extract improve insulin sensitivity in T2D patients, reducing HOMA-IR and fasting insulin. Sulforaphane reduces hepatic insulin resistance by activating Nrf2 and suppressing oxidative stress-driven insulin signaling impairment.

A PMC meta-analysis of whole-grain intake confirmed increased insulin sensitivity as a key protective mechanism against type 2 diabetes. A human clinical trial (n=36 obese participants) with heat-treated resistant-starch-rich brown rice showed HOMA-IR decreased significantly over 2 weeks (p=0.021). Mouse model data also demonstrated that short-chain fatty acids derived from brown rice fermentation negatively correlated with HOMA-IR.

Brussels sprouts contain alpha-lipoic acid (ALA) and glucosinolate-derived isothiocyanates with documented effects on insulin signaling and glucose metabolism. Soluble fiber slows glucose absorption. Cruciferous vegetable RCT evidence shows improved glycaemic control. Animal models demonstrate isothiocyanates improve insulin sensitivity.

Animal studies show tributyrin prevents high-fat-diet-induced insulin resistance via GPR109A signaling, and improves glucose metabolism and insulin responsiveness in obese mice. Human evidence is based on butyrate-class trials, including one RCT showing improved metabolic parameters with sodium butyrate in obese subjects. Tributyrin-specific human insulin sensitivity RCTs have not been published.

Butyrate supplementation improves insulin sensitivity in lean/healthy individuals and in mouse models of high-fat diet-induced insulin resistance. Human evidence is strongest in non-obese subjects, while results in metabolic syndrome populations are mixed.

In metabolic syndrome subjects, the campesterol:cholesterol ratio is negatively correlated with plasma insulin, suggesting that higher campesterol absorption efficiency is associated with lower insulin levels. This relationship is observational and reflects campesterol as a metabolic marker rather than a direct insulin sensitizer. No interventional evidence for campesterol improving insulin sensitivity as a primary outcome exists.

Capsaicin and capsiate have been shown to enhance insulin sensitivity in diabetic animal models via AMPK activation and hepatic glucose regulation, with TRPV1-mediated mechanisms. Human mechanistic data support the link, though large human RCTs specifically targeting insulin sensitivity remain limited.

Capsanthin dose-dependently increased AMPK phosphorylation and adiponectin in HFD mice, markers of improved insulin sensitivity. Reversal of glucose intolerance in obesity models and adrenoceptor-β2 agonism-driven fatty acid oxidation further support this link.

Several clinical and animal studies support C. cassia's role in improving insulin sensitivity, primarily through enhanced insulin receptor signaling and GLUT4 translocation. Results in human trials are mixed: one well-designed RCT in impaired glucose tolerance subjects using euglycemic clamp methodology found no effect, while other RCTs in T2DM showed improvements in fasting glucose consistent with sensitivity gains.

Catechins enhance peripheral insulin sensitivity through GLUT-4 translocation, AMPK activation, and reduction of NF-κB/NLRP3-mediated β-cell damage and insulin resistance. RCTs and meta-analyses confirm catechin-associated improvements in insulin sensitivity, particularly in metabolically compromised populations.

Cowpea-derived peptides have been shown in vitro to activate the Akt/PKB signaling pathway, which mediates insulin sensitivity in cells. Cowpea protein hydrolysates also inhibit DPP-IV and carbohydrate-digesting enzymes relevant to glucose homeostasis. These mechanisms place catjang cowpea firmly in the scientific discussion on insulin-sensitizing legumes.

Sulforaphane from cauliflower activates AMPK and Nrf2, reducing oxidative-stress-driven insulin resistance. Human RCTs with crucifer-derived SFN demonstrate significant reductions in fasting insulin and HOMA-IR in type 2 diabetic patients. The fiber content additionally modulates postprandial insulin response.

Capsaicin activates TRPV1 receptors in insulin-sensitive tissues and has shown effects on insulin secretion and glucose uptake in human studies. An OGTT study in healthy volunteers found oral capsaicin increased plasma insulin and attenuated post-load blood glucose. Animal data are robust; confirmatory human RCTs are limited.

Chia seeds' ALA, fiber, and antioxidant content have been linked to improved insulin sensitivity in animal studies and inferred from clinical glycemic data. A systematic review found modest improvements in glycemic markers across 14 RCTs. Fiber-mediated slowing of carbohydrate absorption reduces postprandial insulin demand.

Chickpea protein hydrolysates contain DPP-IV inhibitory peptides that preserve active GLP-1, supporting insulin secretion and peripheral glucose uptake. Controlled diet studies demonstrate decreased plasma insulin concentration with chickpea supplementation. Colonic fermentation of chickpea fibre produces SCFAs that enhance insulin sensitivity at the hepatic and peripheral level.

Multiple RCTs demonstrate that chicory inulin supplementation improves insulin sensitivity in adults with overweight, obesity, or prediabetes, mediated through colonic SCFA production and gut microbiota modulation. Effects appear strongest in individuals with impaired fasting glucose rather than post-load glucose impairment.

RCTs in NAFLD patients and a 2025 GRADE meta-analysis confirm that chlorella supplementation significantly reduces HOMA-IR (a validated marker of insulin resistance). Chlorella's polysaccharides, magnesium, and fiber are mechanistically linked to improved insulin signaling.

In vitro and animal studies demonstrate chokeberry polyphenols improve insulin sensitivity via α-glucosidase and DPP-4 inhibition and modulation of adipogenic signalling. Some human trials in metabolic syndrome report improved glycaemic markers, though a dedicated RCT in type 2 diabetics found no significant effect on insulin sensitivity. Evidence is promising but not conclusive in humans.

Chromic chloride and other trivalent chromium forms have been investigated for improving insulin sensitivity, primarily in insulin-resistant populations. The proposed mechanism involves chromodulin-mediated activation of insulin receptor tyrosine kinase and enhanced GLUT-4 trafficking. Results are mixed: some studies show benefit in insulin-resistant subjects while others, including a rigorous clamp study in healthy subjects, found no improvement.

Chromium, particularly as chromium picolinate, has been studied extensively as an insulin sensitizer. A systematic review and meta-analysis of 20 RCTs with 1,147 cases found significant reductions in HOMA-IR (pooled MD = −1.29) in patients with T2DM, prediabetes, and confirmed insulin resistance. Evidence is mixed in non-diabetic individuals but more consistent in those with impaired glucose metabolism.

Chrysin and its bioavailability-enhanced formulations improve insulin sensitivity in rodent models of type 2 diabetes and diet-induced insulin resistance. Mechanisms include GLUT4 upregulation, AMPK/PI3K/AKT activation, and gluconeogenesis suppression. Glucose tolerance test and HOMA-IR outcomes are significantly improved with the phytosome formulation. Evidence is entirely preclinical.

Cinnamon polyphenols (type-A proanthocyanidins, cinnamaldehyde) have been identified as insulin sensitizers that activate insulin receptor signaling and promote GLUT4 translocation. Multiple clinical trials and a systematic review/meta-analysis confirm improvements in fasting blood glucose and lipid profiles in T2DM patients, though results are mixed and evidence for direct insulin sensitivity improvement in non-diabetic individuals is less robust.

RCTs and a meta-analysis of hesperidin from C. sinensis show improved insulin sensitivity indices in humans, including QUICKI scores. Preclinical evidence demonstrates GLUT4 translocation and PPAR-γ activation as mechanisms. A 6-month RCT in prediabetic subjects found meaningful insulin-related improvements.

CLA's effects on insulin sensitivity are isomer-specific and population-dependent. The c9,t11 isomer shows improvement in some populations (obese children, sedentary young adults, NAFLD patients), while the t10,c12 isomer may worsen insulin sensitivity in obese men with metabolic syndrome.

Multiple RCTs and meta-analyses demonstrate that cocoa flavanols improve insulin sensitivity, particularly in individuals with insulin resistance. A meta-analysis of 19 RCTs found significant improvements in fasting insulin (WMD −2.33 μU/mL) and HOMA-IR (WMD −0.93). The mechanisms involve nitric oxide-mediated vascular effects and antioxidant protection of insulin signaling.

EPA and DHA in cod liver oil improve insulin sensitivity through reduced inflammation and altered adipocyte lipid metabolism. A double-blind RCT in gestational diabetes patients found CLO significantly reduced HOMA-IR and fasting glucose compared to placebo. Omega-3s have been shown to improve insulin resistance in obese and non-obese patients with an inflammatory phenotype.

Chlorogenic acid in coffee fruit has been proposed to improve insulin resistance via hepatic glucose-6-phosphatase inhibition and reduced adipogenesis. Human RCT data with CGA-rich green coffee extracts show directional improvements in HOMA-IR and insulin sensitivity markers in overweight and metabolic syndrome populations, though not all trials show significant effects on insulin levels.

Coix seed extracts improve insulin resistance in multiple T2DM and NAFLD mouse models, partly via AMPK pathway activation and gut microbiota-mediated SCFA production. Coix prolamin hydrolysates inhibit DPP-IV, a pharmacological mechanism used by approved antidiabetic drugs.

A 12-week double-blind RCT found Coleus forskohlii extract significantly improved insulin concentration and HOMA-IR insulin resistance index compared to placebo in overweight/obese adults. Preclinical data support cAMP-enhanced beta-cell insulin secretion as the primary mechanism.

Coptis chinensis (Chinese goldthread) is the primary botanical source of berberine in Traditional Chinese Medicine, used for millennia for conditions including diabetes ('Xiao Ke'). Standardized extracts improve insulin sensitivity and lower HOMA-IR through berberine-mediated AMPK activation, confirmed in multiple RCTs and systematic reviews.

Clinical RCTs demonstrate that CoQ10 supplementation reduces HOMA-IR, a validated index of insulin resistance, in both prediabetic and type 2 diabetic populations. A randomized double-blind placebo-controlled trial of 80 patients with impaired glucose tolerance showed significant HOMA-IR reduction after 8 weeks of CoQ10. The mechanism involves reduced oxidative stress restoring mitochondrial efficiency in insulin-sensitive tissues.

Cordyceps extracts improve insulin sensitivity in diabetic animal models by upregulating IRS-1 and GLUT-4 expression, increasing pyruvate kinase activity, and reducing HOMA-IR. Myriocin-like compounds in Cordyceps inhibit ceramide biosynthesis, which is a recognized pathway contributing to insulin resistance. Animal data is robust; human trial evidence is very limited.

Soluble corn fiber (SCF) has been shown in human studies to lower postprandial insulin response, and corn silk extract improved insulin levels in high-fat diet animal models. SCF's prebiotic fermentation produces SCFAs that enhance peripheral insulin sensitivity. This constitutes scientific evidence at the clinical level for SCF.

Corn silk extract has been shown in animal studies to improve insulin sensitivity by recovering damaged pancreatic beta-cells, elevating insulin secretion, and reducing insulin resistance. A 12-week study in obese mice found significant declines in insulin resistance value and serum insulin in high-calorie diet groups treated with corn silk.

Corosolic acid, the primary bioactive of banaba (Lagerstroemia speciosa) leaf, improves insulin sensitivity through AMPK activation and PPAR-γ/PPAR-α upregulation. A 12-week RCT in prediabetics (n=45) with 300 mg/day banaba extract containing 0.3% corosolic acid significantly reduced HbA1c, fasting plasma glucose, and HOMA-IR compared to placebo.

Creatine may improve insulin sensitivity through enhanced GLUT-4 translocation and increased muscle glucose uptake, particularly when combined with exercise. Clinical evidence is mixed: some trials in insulin-resistant and type 2 diabetic populations show benefit, while studies in healthy untrained individuals show no effect on insulin action.

Creatine monohydrate, especially combined with exercise, supports insulin sensitivity primarily through enhanced GLUT-4 transporter activity in skeletal muscle. Clinical trials in type 2 diabetic populations show improved glycemic control when creatine is added to an exercise program.

Serum BCX is inversely associated with insulin resistance indices in non-diabetic humans. BCX enhances p-IRS-1 signaling and PPAR-α expression in insulin-resistant rodents, and mechanistic studies show it reduces M1 macrophage-driven chronic inflammation that causes insulin resistance.

Clinical evidence indicates cumin supplementation can improve insulin sensitivity markers including HOMA-IR. An 8-week RCT in overweight adults found cumin had effects comparable to orlistat on insulin metabolism. Results are more robust in diabetic than in non-diabetic populations.

Curcumin, the principal curcuminoid from turmeric (Curcuma longa), improves insulin sensitivity by reducing inflammation, activating AMPK, inhibiting NF-κB, and modulating adipokines. An evidence-based review of human RCTs found curcumin improved glycaemic control in T2DM, and the NIH Endotext lists it among anti-diabetic herbs studied in clinical trials.

D-Pinitol, a methylated inositol found in legumes and carob, acts as an insulin mimetic and reduces insulinemia and HOMA-IR in animal models. It has been investigated for insulin sensitization due to its structural similarity to inositol mediators in insulin signaling, and human studies show it may improve glycemic markers in insulin-resistant individuals.

Daidzin and its aglycone daidzein improve insulin sensitivity in animal models via PPAR-γ activation, GLUT4 upregulation, and AMPK phosphorylation. Animal studies show reduced HbA1c, improved glucose utilization, and preserved beta-cell function. Human clinical evidence is limited.

Damulin A is a specific gypenoside from Gynostemma pentaphyllum identified as a direct AMPK activator. It improves insulin sensitivity through AMPK-mediated GLUT4 translocation and suppression of hepatic gluconeogenesis in preclinical models, representing a key mechanistic active constituent.

Dandelion leaf extracts have been shown in animal models to reduce insulin resistance via AMPK pathway activation. Chicoric and chlorogenic acids may improve glucose transporter activity. A human RCT in type 2 diabetics showed significant fasting blood glucose reduction with dandelion leaf/root powder. Evidence is promising but predominantly preclinical.

A randomized double-blind study found that 50 mg/day DHEA for one year improved glucose tolerance in older adults with abnormal baseline glucose tolerance, reduced plasma triglycerides, and lowered inflammatory cytokines IL-6 and TNFα. However, a 2-year RCT in elderly men and women found no improvement in insulin secretion or action, and overall evidence is mixed.

Dioscorea constituents, particularly polysaccharides and dioscorin, have demonstrated improved insulin sensitivity and reduced insulin resistance in rodent models. Mechanistic evidence points to GLUT4 upregulation, DPP-IV inhibition, and enhanced β-cell function. No robust human trials yet exist.

DHA has shown inconsistent effects on glycemic control in RCTs. A USDA-funded RCT in hypertriglyceridemic men found DHA improved lipocentric but not glucocentric markers of insulin sensitivity. DHA and EPA have been shown to differentially alter gut microbiota and may reverse high-fat diet-induced insulin resistance in animal models, though human RCT evidence is mixed.

DPA has been associated with improvements in insulin sensitivity in animal models, with proposed mechanisms including GPR120 and PPARγ activation. The 2019 review of DPA's biological role specifically lists insulin sensitivity improvement among its metabolic disease risk marker effects. Human-specific evidence for DPA on insulin sensitivity remains preliminary.

EGCG, the predominant catechin in green tea, improves insulin sensitivity through multiple mechanisms including GLUT4 translocation promotion, PTP1B inhibition, and anti-inflammatory actions in skeletal muscle, liver, and adipose tissue. In vitro studies confirm suppression of insulin resistance and glucose uptake enhancement; human evidence from green tea studies shows reductions in fasting glucose in some populations.

Swertiamarin, the principal secoiridoid glycoside isolated from E. littorale, has been shown to improve insulin sensitivity in NIDDM rat models by targeting PPAR-γ and modulating key metabolic genes. Animal studies demonstrate restoration of glucose transporter expression and normalization of hepatic and adipose tissue gene profiles associated with insulin resistance.

Eucommia leaf extract reduces HOMA-IR in fructose-fed rats and quercetin glycoside from the leaf improves insulin signaling in hepatocyte models. Mechanisms include enhanced PI3K/Akt/GLUT4 signaling and inhibition of IRS-1 serine phosphorylation. Evidence is preclinical.

Fava beans' soluble fiber, resistant starch, and bioactive peptides support insulin sensitivity through multiple mechanisms including slowed glucose absorption, DPP-IV inhibition, and GLP-1 modulation. A legume-rich low-GI diet RCT demonstrated significantly greater HbA1c reductions vs. high-wheat-fiber control in type 2 diabetics.

Fenugreek seeds contain multiple bioactive compounds—including 4-hydroxyisoleucine, saponins, and fiber—that collectively improve insulin sensitivity, glucose-dependent insulin secretion, and glycemic control. Clinical trials have shown fenugreek improves blood glucose, insulin resistance, and lipid profiles in T2DM patients. The NIH Endotext lists it as both a carbohydrate absorption inhibitor and an insulin sensitizer.

Ferulic acid improves insulin sensitivity by activating the PI3K/Akt signaling pathway, downregulating lipogenic gene expression (SREBP1c, FAS, ACC), and reducing hepatic lipid accumulation that drives insulin resistance. Animal models consistently show reduced HOMA-IR and improved glucose tolerance. No dedicated human insulin-sensitivity RCT has been published, but mechanistic evidence is well characterized.

Fisetin improves insulin sensitivity and reduces HOMA-IR in multiple diabetic and metabolic syndrome rodent models through SIRT1/AMPK pathway activation and reduction of inflammation-driven insulin resistance. No human trials exist.

Fish oil omega-3s may improve insulin sensitivity through anti-inflammatory mechanisms, including upregulation of PPAR-γ expression and downregulation of TNF-α and IL-1—cytokines that impair insulin signaling. Several RCTs in T2DM and gestational diabetes patients demonstrate improvements in HOMA-IR and related parameters, though direct fasting glucose effects are modest.

Meta-analyses of RCTs demonstrate flaxseed supplementation significantly improves insulin sensitivity markers (HOMA-IR, QUIKI index, fasting insulin). Effects are strongest with whole or ground flaxseed and in populations with type 2 diabetes, prediabetes, or metabolic syndrome.

A 12-week double-blind RCT found significant improvement in insulin concentration and insulin resistance in overweight/obese subjects receiving C. forskohlii extract. cAMP-mediated enhancement of beta-cell signalling and reduced adiposity are the proposed mechanisms.

FOS fermentation-derived SCFAs influence insulin signaling via GPR41/43 activation and GLP-1 secretion, and animal data show FOS reduces HOMA-IR and abdominal fat. Human evidence is mixed: meta-analyses show benefit primarily in diabetic or prediabetic populations, while a 2025 RCT found FOS did not improve insulin sensitivity in overweight adults (unlike inulin). The overall human evidence is modest and population-dependent.

Gamma oryzanol improves insulin sensitivity through AMPK activation, GLUT4 translocation, and PPAR-α upregulation in preclinical models. A 2025 PMC review found clinical evidence supporting improved insulin sensitivity and glucose metabolism in metabolic syndrome patients. Animal studies demonstrate reduced HOMA-IR with supplementation.

Preclinical evidence shows Ganoderma lucidum extract activates AMPK to improve insulin sensitivity, and human clinical data show reductions in HOMA-IR. Some RCT evidence in type 2 diabetes supports improvements in fasting glucose and HbA1c, though a larger 16-week RCT found no effect.

Clinical and preclinical studies demonstrate that chickpea consumption and chickpea bioactive compounds (resistant starch, soluble fiber, isoflavones including biochanin A) can improve insulin sensitivity by slowing glucose absorption, stimulating incretin release, and modulating gut-hormone signaling. A review in Nutrients (PMC5946219) summarized clinical evidence that legumes including chickpeas reduce insulin resistance parameters.

Geniposide and genipin from Gardenia jasminoides improve insulin sensitivity through PPAR-γ and PPAR-α activation and UCP2 inhibition. A pilot clinical study showed geniposide reduced insulin resistance and liver fibrosis markers in NAFLD patients. GJ aqueous extract improved insulin sensitivity in steroid-induced insulin-resistant rats.

Genipin from Gardenia jasminoides inhibits UCP2 in pancreatic beta cells, reversing obesity- and high-glucose-induced insulin secretion dysfunction. Geniposide acts as a GLP-1 receptor agonist to enhance glucose-dependent insulin release. In aged rats, genipin administration significantly reduced hyperinsulinemia and hyperglycemia. These are preclinical mechanistic findings.

Clinical meta-analyses confirm garlic improves fasting blood glucose and HbA1c in T2DM patients, and experimental and clinical investigations show beneficial effects on insulin resistance linked to NAFLD pathogenesis. Allicin and organosulfur compounds are proposed to enhance insulin signaling and hepatic glucose metabolism.

Garlic supplementation improves insulin sensitivity and reduces HOMA-IR in clinical trials. Mechanisms include allicin-mediated pancreatic beta-cell protection, enhanced insulin receptor signaling, and AMPK activation. An RCT in 110 NAFLD patients found garlic powder significantly reduced insulin and HOMA-IR versus placebo.

RCTs demonstrate genistein improves insulin sensitivity indices including HOMA-IR and QUICKI in postmenopausal women with T2DM and in obese individuals with insulin resistance. A 2025 meta-analysis confirmed significant reductions in fasting insulin (MD −1.79) and HOMA-IR (MD −0.56) versus placebo.

Ginger supplementation has been shown in RCTs and meta-analyses to improve insulin sensitivity markers including HOMA-IR, fasting insulin, and QUICKI in type 2 diabetic patients. A 2018 meta-analysis found ginger showed a significant beneficial effect on glucose control and insulin sensitivity. Ginger reduces oxidative stress in pancreatic beta cells and modulates insulin receptor signaling.

Ginseng, particularly American ginseng (Panax quinquefolius) and Asian ginseng (Panax ginseng), has been studied as an insulin sensitizer. The NIH Endotext explicitly lists American ginseng among insulin sensitizers studied in diabetes patients. Ginsenosides improve insulin secretion, reduce insulin resistance, and improve postprandial glucose control in clinical trials.

Ginsenosides are the primary active saponin glycosides of Panax ginseng and P. quinquefolius responsible for insulin-sensitizing effects. They activate PPAR-γ, stimulate GLUT4 translocation, and improve beta-cell function. Clinical evidence from ginseng RCTs demonstrates reductions in postprandial glucose, fasting insulin, and HOMA-IR.

Glucomannan reduces postprandial insulin surges and has been shown to lower HOMA-IR in clinical trials in T2DM patients. By slowing gastric emptying and carbohydrate absorption, it attenuates insulin demand, and the resulting lower chronic hyperinsulinemia may improve peripheral insulin sensitivity over time.

Low circulating glycine is a robust metabolic biomarker of insulin resistance, and human studies show glycine supplementation increases insulin secretion in at-risk populations. GlyNAC (glycine + N-acetylcysteine) RCTs in older adults documented correction of insulin resistance alongside restored glutathione. Animal models show glycine improves hepatic insulin signaling via glutathione-mediated reduction of oxidative stress.

Soy isoflavone preparations containing glycitein have been investigated for insulin-sensitizing effects, with mixed but suggestive clinical evidence. A 2021 meta-analysis of RCTs in type 2 diabetes reported improvements in glycemic control metrics with soy isoflavone supplementation. Animal model data show reductions in insulin resistance markers with isoflavone fractions that include glycitein.

LBP has demonstrated the ability to improve insulin sensitivity in animal models and has shown glycemic benefits in human trials. Preclinical work shows LBP improves hepatic insulin signaling and reduces insulin resistance in diabetic rodents. A human RCT in type-2 diabetics showed glycemic improvements with 300 mg/day LBP. Reviews confirm LBP's insulin-sensitizing effects are among its key metabolic properties.

Multiple clinical studies and a 2023 meta-analysis of RCTs show amla lowers fasting blood glucose and post-prandial glucose in diabetic and prediabetic subjects, consistent with insulin-sensitizing effects. Some animal and pilot human studies show improved insulin sensitivity specifically.

Resveratrol and GSE both have documented effects on insulin sensitivity in human RCTs. A red wine extract study (8 weeks, 12 subjects) decreased HOMA-IR and upregulated SIRT1. An RCT in Iranian adolescents with metabolic syndrome tested 8-week GSE supplementation on insulin resistance. Resveratrol polyphenols enhance glucose uptake via AMPK/GLUT4 pathways demonstrated in clinical pharmacology studies.

GSE has demonstrated significant improvements in insulin resistance (HOMA-IR) and insulin concentration in RCTs in T2DM and metabolic syndrome patients. Mechanisms include reduction of oxidative stress impairing insulin receptor function and potential alpha-glucosidase inhibition. An 8-week RCT in adolescents with metabolic syndrome confirmed significant improvement in insulin resistance.

Grapefruit's flavonoid naringenin has been shown to reduce insulin resistance in animal and early human studies, including an 18% reduction in fasting insulin in one clinical trial. Subgroup analyses of RCTs in metabolic syndrome patients show greater 2-hour insulin reductions with grapefruit versus placebo. The mechanism involves PPAR-α/γ activation and AMP kinase signaling.

Green tea contains catechins (primarily EGCG) that improve insulin sensitivity through GLUT4 translocation, PTP1B inhibition, and anti-inflammatory mechanisms. The NIH Endotext notes green tea reduced fasting blood glucose in 1 of 3 small human trials. Multiple systematic reviews support its role in glucose metabolism, particularly in insulin-resistant individuals.

Guarana polyphenols, including catechin and epicatechin, support insulin sensitivity by inhibiting alpha-glucosidase, reducing LDL oxidation, and modulating inflammation and oxidative stress. Human epidemiological data show lower rates of hyperinsulinemia and metabolic syndrome in habitual guarana consumers. Preclinical models show prevention of insulin resistance in dietary obesity models.

Gymnema (Gymnema sylvestre) has Ayurvedic roots as 'gurmar' (sugar destroyer) and multiple clinical trials confirm reductions in fasting and postprandial blood glucose and HbA1c. A systematic review and meta-analysis of 10 RCTs (n=419) demonstrated significant glycemic improvements. It enhances insulin secretion and insulin sensitivity through gymnemic acids acting on pancreatic beta cells and peripheral tissues.

Gymnema sylvestre has been used in Indian Ayurvedic medicine for diabetes ('gurmar' or 'sugar destroyer') for centuries and has been studied in multiple clinical trials. A systematic review and meta-analysis of 10 studies (n=419) found significant reductions in fasting blood glucose, postprandial blood glucose, and HbA1c. A double-blind RCT demonstrated effects on both insulin secretion and insulin sensitivity in metabolic syndrome patients.

Gypenosides are the bioactive saponin constituents of Gynostemma pentaphyllum responsible for insulin-sensitizing effects. They directly activate AMPK (including the specific damulin A and B isoforms), improving glucose uptake, reducing hepatic glucose production, and lowering insulin resistance markers in both animal models and clinical studies.

Hesperidin/hesperetin has shown glucose-lowering and insulin-sensitizing properties in animal models and some human trials, though effects on fasting blood glucose and HOMA-IR in human meta-analyses have not reached statistical significance consistently. Anti-inflammatory mechanisms (TNF-α, IL-6 reduction) may mediate modest insulin-sensitizing effects.

Hesperidin has shown improvement of the quantitative insulin sensitivity check index (QUICKI) in a 2024 meta-analysis of RCTs. In vitro evidence demonstrates hesperidin alleviates insulin resistance in human hepatocytes. Effects are primarily observed in higher-risk populations at doses above 500 mg/day for at least 6 weeks.

Hibiscus sabdariffa bioactive compounds have been proposed to improve insulin sensitivity by increasing glucose uptake in muscle and adipose tissue, elevating GLP-1, and reducing insulin resistance markers. A clinical study found HS tea reduced postprandial insulin response, and animal models consistently support improved insulin signaling.

A human RCT in exercised athletes found HCA supplementation lowered post-meal insulin response while enhancing muscle glycogen synthesis, suggesting improved insulin action in skeletal muscle. Animal studies further show HCA alleviates diet-induced insulin resistance. Human evidence is limited to small studies.

Bael extracts have been shown to significantly improve insulin resistance markers (HOMA-IR) in diabetic animal models, with evidence that the hypoglycemic effect is largely mediated through reduction of peripheral insulin resistance rather than direct insulin secretion alone. This supports the traditional antidiabetic use of bael leaves.

Inositol, particularly myo-inositol and D-chiro-inositol, functions as a second messenger in the insulin signaling pathway and has been shown in RCTs to improve insulin sensitivity in metabolic syndrome, PCOS, and T2DM. A clinical trial showed that the 40:1 physiological ratio of myo-Ins:D-chiro-Ins improved fasting blood glucose and HbA1c in T2DM patients.

Multiple RCTs and a pilot controlled feeding trial demonstrate that inulin supplementation improves peripheral insulin sensitivity and reduces fasting insulin in adults at risk for or with type 2 diabetes. SCFAs generated from inulin fermentation stimulate GLP-1 and reduce endotoxin-driven insulin resistance. Effects are most pronounced in insulin-resistant populations.

Isoleucine uniquely among the BCAAs stimulates insulin-independent glucose uptake in skeletal muscle, producing an acute blood glucose-lowering effect confirmed in both animal and human studies. However, chronically elevated isoleucine (as seen in obesity) is observationally associated with insulin resistance, suggesting a dose- and context-dependent relationship. Dietary isoleucine restriction in mice markedly improves hepatic insulin sensitivity via the FGF21-UCP1 axis.

Animal models consistently show IMO prevents HFD-induced insulin resistance and normalizes insulin and glucagon levels. Human clinical data are limited but suggest a modest improvement in fasting glucose. IMO's prebiotic action on gut microbiota may contribute to improved insulin signaling through SCFA-mediated pathways.

Jiaogulan (Gynostemma pentaphyllum) is the same plant known by its Chinese name, used in traditional medicine as an adaptogen and metabolic herb. Its gypenosides activate AMPK, and clinical trials have shown significant reductions in insulin resistance (HOMA-IR) in NAFLD patients and improvements in blood glucose in T2DM/prediabetic populations.

The slowly digestible starch and resistant starch in kidney beans reduce postprandial insulin excursions, and the alpha-amylase inhibitor phaseolamin limits carbohydrate absorption, together supporting insulin sensitivity. Clinical studies show reduced postprandial insulin and reduced risk of insulin resistance with regular legume consumption.

A meta-analysis of 15 RCTs (896 T2DM patients) found resveratrol significantly reduced HOMA-IR (WMD: −0.99; p=0.002), a validated measure of insulin resistance. A pilot RCT specifically using knotweed-derived trans-resveratrol examined insulin resistance in obese men with metabolic syndrome. Resveratrol activates SIRT1 and AMPK pathways to improve insulin signaling.

Perioperative IV alanyl-L-glutamine improves insulin sensitivity indices in surgical patients, as shown in a dedicated RCT. Glutamine supplementation in critical illness also attenuates insulin resistance associated with catabolic stress. These findings extend to patients with COPD and respiratory failure receiving parenteral AG.

L-arginine improves insulin sensitivity primarily through the NOS/NO pathway, which enhances glucose disposal in peripheral tissues and reduces hepatic glucose production. Clinical trials in type 2 diabetic patients show that L-arginine (3–8.3 g/day) significantly improves both peripheral and hepatic insulin sensitivity. A meta-analysis confirms near-significant reductions in HOMA-IR and significant reductions in serum insulin.

Multiple meta-analyses of RCTs demonstrate L-carnitine supplementation reduces HOMA-IR and fasting insulin in patients with insulin resistance. Mechanism involves improved mitochondrial fatty acid oxidation, acetylcarnitine formation in skeletal muscle, and activation of pyruvate dehydrogenase. A 2025 RCT in type 2 diabetics confirmed improved insulin-induced suppression of endogenous glucose production.

L-carnosine (2 g/day for 12–14 weeks) attenuated increases in fasting insulin and insulin resistance in overweight non-diabetic adults, and increased the Matsuda insulin sensitivity index in pre-diabetics and T2D patients when controlling for sex and obesity status. In vitro evidence shows carnosine increases insulin-stimulated glucose uptake in human skeletal muscle cells.

A randomized double-blind placebo-controlled trial in 54 type 2 diabetic patients showed that 3 g/day L-citrulline for 8 weeks significantly reduced fasting blood glucose and HbA1c, though it did not improve QUICKI or HOMA-β measures of insulin sensitivity. A separate RCT in middle-aged/older adults with type 2 diabetes found 4 weeks of L-citrulline improved FMD, pulse wave velocity, and blood glucose. Animal studies confirm the mechanism involves inhibition of serine phosphorylation of insulin receptor substrate-1 (IRS-1), improving hepatic insulin signaling.

L-cysteine and NAC improve insulin sensitivity in diabetic animal models by upregulating glutathione and adiponectin and increasing GLUT-4 translocation. Human data show that L-cysteine/GSH levels negatively correlate with insulin resistance in type 2 diabetic patients. Clinical trials with cysteine-rich proteins in type 2 diabetic humans have shown improved insulin-stimulated glucose clearance.

A double-blind placebo-controlled RCT demonstrated that oral glutathione (1000 mg/day for 3 weeks) significantly increased whole-body insulin sensitivity in obese subjects with and without type 2 diabetes, measured by hyperinsulinemic-euglycemic clamp. Skeletal muscle GSH increased by ~19% in the supplemented group.

Low plasma glycine is a robust biomarker of insulin resistance, and multiple clinical studies show glycine supplementation improves insulin secretion, sensitivity, and postprandial glucose control. GlyNAC RCTs also demonstrate correction of insulin resistance in older adults. Mechanistically, glycine may enhance GLP-1 secretion and improve pancreatic beta-cell function.

A rigorous 12-week RCT demonstrated that 4 g/day L-histidine significantly reduced HOMA-IR (insulin resistance index) in obese women with metabolic syndrome, alongside reductions in inflammatory cytokines. Cross-sectional studies in obese populations also show dietary histidine intake to be inversely associated with insulin resistance.

Isoleucine uniquely promotes insulin-independent glucose uptake in skeletal muscle via a PI3K-mediated pathway not involving mTOR. Multiple human and mechanistic studies confirm this effect lowers postprandial blood glucose without proportional increases in insulin secretion. This insulin-sensitizing action is documented as stronger for isoleucine than for leucine.

Leucine's effects on insulin sensitivity are bidirectional and dose-dependent: acutely it amplifies insulin secretion and improves glucose clearance; however, chronic high-dose leucine activates mTORC1→S6K1→IRS-1 serine phosphorylation, causing reversible insulin resistance in animal models. Human clinical data show co-ingestion with glucose synergistically lowers postprandial glucose, while concerns about long-term BCAA elevation in obesity complicate the picture.

The relationship between L-valine and insulin sensitivity is primarily one of risk when elevated: high circulating valine is associated with insulin resistance and type 2 diabetes in multiple human cohorts. The catabolite 3-HIB impairs skeletal muscle insulin signaling and has been found elevated in human diabetic subjects. Dietary valine restriction in animal models improved insulin sensitivity, suggesting excess valine negatively modulates insulin signaling.

Multiple intervention trials and prospective studies demonstrate that higher LA intake or biomarker levels are associated with improved insulin sensitivity. LA-rich dietary fat substitution for saturated fat significantly improves insulin sensitivity in controlled clinical trials. A pooled global analysis confirms the association between LA biomarkers and reduced T2DM risk.

L. casei strains have been studied in metabolic syndrome and obesity contexts for their effects on insulin resistance markers. The 2024 LC2W RCT examined insulin-related endpoints in high-risk MetS subjects. Mechanisms involving SCFA production, GLP-1 modulation, and reduction of LPS-driven insulin resistance provide a plausible biological rationale supported by emerging clinical data.

Preclinical evidence from a 2025 Journal of Biomedical Science study reports that oral L. crispatus (10⁸ CFU/day) significantly improved insulin sensitivity and reduced hepatic steatosis in a diet-induced cardiometabolic disorder mouse model — described as the first such report for this species. The mechanism is proposed to involve SLP-mediated epithelial barrier reinforcement and PPAR-γ upregulation reducing NF-κB–driven cytokine release. Human clinical evidence is not yet available.

L. gasseri strains have been shown in animal models to improve insulin sensitivity through multiple mechanisms including SCFA production, reduction of gut-derived inflammation, and direct pancreatic effects. L. gasseri SBT2055 improved insulin secretion in diabetic rats; CKCC1913 reduced insulin resistance in high-fat diet mice. Human RCT evidence is emerging but limited.

Meta-analyses of RCTs show L. plantarum supplementation reduces fasting glucose and HOMA-IR trends in T2DM and prediabetes populations, with significant glucose effects confirmed. Broader meta-analyses confirm probiotic benefits on insulin resistance.

L. rhamnosus GG improves insulin sensitivity in high-fat-diet animal models by enhancing GLUT4 expression in skeletal muscle, increasing adiponectin, and activating AMPK. A 90-day RCT showed LGG stabilized HbA1c in middle-aged adults. HN001 in pregnancy reduced fasting conjugated bile acids correlated with improved insulin indices.

In vitro and in vivo studies indicate lignans enhance insulin sensitivity through multiple mechanisms including modulation of glucose transporter expression, antioxidant action, and GLP-1 pathway activation. Human meta-analyses of flaxseed supplementation confirm significant reductions in HOMA-IR in people with prediabetes and T2DM, though isolated lignan trials show mixed results on direct insulin sensitivity measures.

Luteolin improves insulin sensitivity in animal models of diet-induced obesity and diabetes, inhibiting insulin resistance through toll-like receptor and AMPK signaling pathways. A human RCT using a luteolin-containing nutraceutical measured HOMA-IR as an endpoint.

Lychee seed saponins and extracts have demonstrated improvement of insulin resistance in animal models of type 2 diabetes, with associated reductions in blood glucose and insulin levels. A PMC study in T2DM rats showed lychee seed extract (LSE) significantly decreased glucose, insulin, and advanced glycation end products (AGEs). Improving insulin resistance is identified as a primary mechanistic pathway in multiple peer-reviewed reviews.

MUFA-rich diets, of which macadamia nuts are a primary source, are associated with improved insulin sensitivity. Meta-analyses of tree nut RCTs including macadamia show reduced HbA1c and fasting glucose in diabetic populations. Palmitoleic acid (omega-7), found in unusually high concentrations in macadamia, may improve insulin receptor signaling.

Magnesium supplementation has been shown in systematic reviews and meta-analyses to significantly improve HOMA-IR in diabetic and non-diabetic individuals. A meta-analysis of RCTs found a significant effect on HOMA-IR (WMD: −0.67; p = 0.013), and magnesium deficiency—highly prevalent in T2DM patients—is inversely correlated with insulin sensitivity. Supplementation for more than 4 months shows the most consistent improvements.

Magnolol improves insulin sensitivity in diabetic animal models by increasing GLUT4 protein expression, promoting glucose transport, and reducing insulin resistance. MSKCC cites inhibition of protein tyrosine phosphatase 1B (PTP1B), a negative regulator of the insulin signaling pathway, as an antihyperglycemic mechanism. Human clinical evidence is lacking; all data is preclinical.

Maitake SX-fraction consistently enhances peripheral insulin sensitivity across multiple preclinical models, outperforming standard diabetic drugs in some comparisons. The mechanism involves upregulation of insulin receptor binding and downstream signaling. Limited human case series data support a hypoglycemic effect in type 2 diabetic patients.

Manganese co-factors pyruvate carboxylase and PEPCK in hepatic gluconeogenesis, and preclinical data indicate it directly activates hepatic Akt in insulin signaling. Population studies show sex-specific associations between manganese status and insulin resistance markers.

Human RCTs demonstrate mango consumption improves insulin sensitivity in overweight/obese individuals and those with prediabetes. Mangiferin and gallotannins are believed to modulate glucose metabolism pathways. Improvements in HOMA-IR and Matsuda index have been observed in multiple trials.

A 2018 RCT in 22 obese insulin-resistant women found mangosteen extract (400 mg/day, 26 weeks) reduced HOMA-IR by 53.2% versus 15.2% in controls (p=0.004). γ-Mangostin activates AMPK and PPARγ to enhance glucose uptake and GLUT4 translocation. A 2026 systematic review confirmed this as the strongest human evidence for mangosteen's glycemic effects.

Maqui berry extract demonstrates multiple mechanisms relevant to insulin sensitivity: SGLT1 inhibition, possible AMPK activation, incretin-mediated effects, and reduced postprandial insulin excursions in human clinical trials. In the Alvarado 2016 trial, acute dosing produced dose-dependent reductions in both fasting insulin and postprandial insulinemia in prediabetic adults.

MCTs have been proposed to improve insulin sensitivity through ketone-mediated reduction of glucose dependence and enhanced hepatic fatty acid oxidation. A 6-week feasibility RCT in non-diabetic adults supplementing ~40 g/day MCT found wide inter-individual variability in insulin sensitivity parameters; earlier mechanistic data suggested ~6–9% improvement in insulin-mediated glucose metabolism.

Silymarin, the active flavonolignan complex from Milk Thistle (Silybum marianum), has insulin-sensitizing properties and the NIH Endotext lists it as an insulin sensitizer studied in patients with diabetes. Clinical trials in T2DM and NAFLD patients show reductions in fasting glucose, HbA1c, and insulin resistance markers.

Clinical and animal evidence shows millet seed consumption reduces insulin resistance. A foxtail millet trial in subjects with impaired glucose tolerance demonstrated a significant decrease in insulin resistance (p=0.007) after 12 weeks. Millet fiber and polyphenols modulate glucose-lipid metabolism via short-chain fatty acid production and adiponectin pathways.

Momordica charantia has the strongest scientific evidence base of all its purported uses for insulin sensitivity improvement. A 2025 GRADE-adherent meta-analysis of 25 RCTs found significant reductions in fasting blood glucose, HbA1c, insulin levels, and HOMA-IR in prediabetes and T2D patients. The mechanism is improved peripheral insulin sensitivity rather than increased secretion.

Mogroside V has been shown in vitro to stimulate insulin secretion in pancreatic beta cells, providing a mechanistic basis for glycemic support beyond simple caloric avoidance. Animal studies demonstrate that mogrosides activate AMPK, a pathway associated with improved insulin sensitivity. In vitro evidence also shows protection of beta cells from oxidative stress-induced damage. Human clinical data remain limited but show significant reductions in postprandial insulin response.

Clinical and preclinical studies demonstrate that Morus alba extracts improve insulin sensitivity and reduce insulin resistance markers. Human trials show reductions in fasting insulin and HOMA-IR. Proposed mechanisms include α-glucosidase inhibition, GLUT4 upregulation, and modulation of adipocytokines.

Multiple clinical and preclinical studies show mulberry leaf extract lowers fasting insulin and HOMA-IR, markers of insulin resistance. A 2025 meta-analysis of 15 RCTs confirmed improvement in HOMA-IR alongside glucose lowering. Preclinical evidence points to AMPK pathway activation and modulation of adipocytokines as mechanisms.

NAC has demonstrated improvements in insulin sensitivity in clinical trials in metabolic syndrome and PCOS populations. An RCT in 76 patients with metabolic syndrome found 1800 mg/day NAC for 12 weeks significantly reduced the insulin resistance index (HOMA-IR, p=0.005). NAC also improves insulin sensitivity in PCOS as part of its documented metabolic effects in that population.

Naringin and naringenin improve insulin sensitivity by activating GLUT-4 and PPAR-γ, with supporting human-level evidence from a case study (18% insulin reduction) and inverse population correlations between blood naringenin and insulin resistance. Preclinical evidence across multiple diabetic animal models is extensive.

Clinical RCT data in T2DM and metabolic syndrome patients demonstrate that standardized aqueous neem extract reduces HOMA-IR (insulin resistance index) in addition to improving fasting glucose and HbA1c. These benefits were demonstrated on top of standard metformin therapy. The mechanism likely involves modulation of glucose transporter expression and inhibition of carbohydrate-digesting enzymes.

Randomized clinical trials in type 2 diabetes patients have demonstrated improvements in insulin sensitivity markers following nettle supplementation. A double-blind RCT by Namazi et al. (2011) on 50 T2DM patients using hydro-alcoholic nettle extract over 8 weeks showed improved insulin sensitivity alongside reduced inflammatory markers. Mechanistic pathways include PPARγ agonism, enhanced pancreatic beta-cell function, and inhibition of carbohydrate-digesting enzymes.

The first human evidence of NMN's metabolic effects (Yoshino et al., Science 2021) showed 250 mg/day NMN for 10 weeks significantly improved muscle insulin sensitivity, signaling (mTOR/Akt phosphorylation), and NAD+ turnover in prediabetic postmenopausal women. Pooled meta-analyses in non-diabetic populations show no significant effect, suggesting benefits may be specific to insulin-resistant individuals.

Human and animal evidence supports nopal improving insulin sensitivity and reducing postprandial insulin levels, particularly in individuals with type 2 diabetes or metabolic syndrome. Broiled nopal stems produced approximately 50% reductions in serum insulin in diabetic patients at 180 minutes in clinical trials. A 2-month RCT showed reduced insulin levels after glucose tolerance testing in metabolic syndrome subjects. The mechanism likely involves fiber-mediated slowing of glucose absorption and possible direct effects on insulin signaling.

C. rotundus rhizome extract inhibits DPP-4 and PTP1-B — key insulin signaling regulators — thereby activating the insulin signaling pathway. Animal studies confirm normalization of blood glucose and HbA1c in diabetic models. This provides a mechanistic basis for insulin sensitization.

Oat β-glucan improves glycemic control and reduces postprandial insulin demand in clinical trials, though direct improvements in fasting insulin sensitivity are modest and inconsistent. Whole oat consumption appears more effective than isolated β-glucan extracts for improving insulin-related markers.

Clinical trials and meta-analyses have explored okra's effect on insulin resistance (HOMA-IR) with mixed results. A 2025 meta-analysis of six RCTs found no significant effect on HOMA-IR or insulin levels despite significant FBG and HbA1c reductions. A 2023 clinical trial in impaired glucose tolerance patients specifically reported insulin resistance improvement with okra.

OA enhances insulin sensitivity and suppresses hepatic glucose production in animal models via modulation of the IRS-1/PI3K/Akt/FoxO1 pathway. A 2022 systematic review confirmed these molecular targets across 13 animal studies, though human RCTs are still needed.

A landmark double-blind, placebo-controlled, crossover RCT demonstrated that 12 weeks of olive leaf polyphenols (51.1 mg oleuropein + 9.7 mg hydroxytyrosol/day) produced a 15% improvement in insulin sensitivity and 28% improvement in pancreatic beta-cell responsiveness in overweight middle-aged men. This is the strongest direct human evidence for this link.

EVOO consumption reduces postprandial glycemic response, improves HOMA-IR, and enhances insulin signaling at the gene expression level. PREDIMED data show EVOO intake prevents diabetes onset. An RCT in Type 1 diabetes patients showed EVOO significantly blunted glycemic response to a high-glycemic-index meal.

Multiple RCTs and meta-analyses demonstrate omega-3 supplementation can improve insulin sensitivity and reduce HOMA-IR, particularly in insulin-resistant and T2DM populations. Mechanisms include reduction of pro-inflammatory cytokines, decreased ectopic lipid accumulation, and improved beta-cell function. Results remain context-dependent and inconsistent across all trials.

Replacing dietary saturated fat with omega-6 PUFA (primarily linoleic acid) has been associated with improved insulin sensitivity in meta-analyses. However, dedicated omega-6-only supplementation trials show limited effects on HOMA-IR, fasting insulin, and HbA1c. GLA specifically may influence insulin-regulated desaturase enzyme activity (D6D/D5D), and adequate omega-6 status is associated with appropriate beta-cell function in some cohort data.

Multiple lines of evidence—including human cohort data and mechanistic studies—support palmitoleic acid's role in improving insulin sensitivity. The RISC longitudinal cohort demonstrated circulating palmitoleate to be an independent determinant of whole-body insulin sensitivity. Preclinical models consistently show enhanced insulin signaling, β-cell protection, and reduced hepatic steatosis.

Oleic acid (omega-9) promotes insulin sensitivity through GLUT-4 translocation in adipocytes, AMPK activation in skeletal muscle, and PPAR regulation. Human and experimental studies show oleate prevents saturated-fat-induced insulin resistance. Mediterranean dietary patterns centered on oleic acid are consistently linked to improved insulin sensitivity.

Onion enhances insulin sensitivity through multiple mechanisms including upregulation of GLUT4 translocation, phosphorylation of insulin receptor substrates, and quercetin-mediated α-glucosidase inhibition. Human RCT data show that fresh onion consumption ameliorates insulin resistance in clinical populations.

Ophiopogon root polysaccharides and oligosaccharides have been shown in preclinical models to enhance insulin signaling. MDG-1 activates the PI3K/Akt pathway in diabetic mice, improving insulin sensitivity. OOJ was shown to improve insulin resistance via IRS-1/PI3K/AKT/GSK-3β activation in both rat models and hepatic cell lines. These findings represent mechanistically grounded scientific evidence, though human trials are lacking.

Multiple human trials in subjects with type 2 diabetes or impaired glucose tolerance show that oyster mushroom intake improves postprandial glucose and insulin responses. A dedicated RCT in IGT patients showed β-glucan-rich oyster mushroom powder elevated GLP-1, which stimulates insulin secretion. The 2020 systematic review of 8 trials found insulin-related metabolic improvements.

Palmitic acid is established as a direct inducer of insulin resistance across multiple human-relevant tissue types including hepatocytes, skeletal muscle myotubes, and neuronal cells. It impairs insulin signaling via mitochondrial ROS, ceramide synthesis, and TLR4 activation. The relationship is one of harm to insulin sensitivity rather than support.

POA consistently improves insulin sensitivity in preclinical models, and higher circulating POA is prospectively associated with better insulin sensitivity in humans. An RCT using pure POA in prediabetic adults is ongoing to definitively test this effect.

Pea protein hydrolysates contain DPP-IV and ACE-inhibitory peptides that can modulate insulin secretion pathways. The 2026 RCT showed pea protein produces markedly lower insulin responses versus whey protein for equivalent glucose reduction, suggesting a favorable insulin profile.

A systematic review and meta-analysis of 40 RCTs found peanut and tree nut consumption significantly decreased HOMA-IR and fasting insulin, indicating improved insulin sensitivity. Individual trials corroborate the finding in diabetic and at-risk populations. Fibre, MUFA, magnesium, and arginine in peanuts are plausible mechanistic mediators.

Pear's low glycemic index, high soluble fiber (pectin), and flavonoid content — particularly quercetin — are associated with improved insulin sensitivity. Pear's pectin slows glucose absorption and reduces postprandial insulin demand. Epidemiological data show pear/apple intake associated with reduced type 2 diabetes risk, a surrogate for improved insulin regulation.

Pectin supplementation has been associated with reduced HOMA-IR and fasting insulin in both animal and human combination trials. Mechanisms include delayed glucose absorption, upregulation of insulin receptor signaling, and microbiota-mediated improvements in metabolic inflammation.

Clinical trials demonstrate that berberine from P. amurense significantly improves insulin sensitivity and reduces insulin resistance (HOMA-IR) in type 2 diabetic and prediabetic patients. The glucose disposal rate (GDR) measured by hyperinsulinemic euglycemic clamp improved significantly with berberine in a multicenter RCT. Mechanisms include AMPK activation, enhanced glucose uptake in peripheral tissues, and reduced hepatic gluconeogenesis.

Preclinical data show phytosterols can induce GLUT4 translocation via AMPK and PI3K/Akt pathways, improving glucose uptake. Limited human data from gestational diabetes and combined supplement trials suggest modest improvements in HOMA-IR and insulin sensitivity. Evidence in humans remains preliminary.

Meta-analyses and RCTs confirm Pycnogenol significantly improves fasting blood glucose, HbA1c, and insulin-related cardiometabolic parameters in type 2 diabetic and metabolic syndrome patients. Improvements in endothelial function and glucose metabolism have been validated in double-blind clinical trials.

Psyllium husk (P. ovata) improves insulin sensitivity through multiple mechanisms including slowed glucose absorption, gut microbiota modulation generating short-chain fatty acids, and direct anti-inflammatory action. Animal studies with P. ovata extract show reduction in HOMA-IR alongside improvements in metabolic parameters.

Platycodon root and its polysaccharide fractions have been shown to improve insulin resistance in high-fat-diet and NAFLD animal models, reducing hepatic insulin resistance and improving AMPK-mediated lipid metabolism. Adipokine modulation including adiponectin and leptin normalization has also been demonstrated.

Platycodon polysaccharides and platycodin D improve insulin sensitivity in animal models by inhibiting α-glucosidase/α-amylase, enhancing AMPK phosphorylation, and increasing glucose uptake in skeletal muscle cells. In vitro, platycodon polysaccharides enhanced glucose uptake and intracellular glycogen in insulin-resistant HepG2 cells.

Meta-analyses of RCTs have found pomegranate consumption significantly reduces HOMA-IR and fasting insulin in metabolically compromised subjects, particularly those with diabetes. The 2025 meta-analysis (34 RCTs, 1,500 subjects) found significant reductions in HOMA-IR and insulin with pomegranate use. A 2025 cardiometabolic meta-analysis also confirmed fasting blood glucose reduction.

Naringenin, the aglycone flavonoid abundant in pomelo, improves insulin sensitivity through GLUT4 upregulation, PPARγ/α activation, and AMP kinase stimulation in preclinical models. A case study in a diabetic human subject showed 150 mg naringenin three times daily for 8 weeks improved resting metabolic rate and insulin response. Human observational data confirm inverse correlation between naringenin plasma levels and insulin resistance.

Prickly pear cactus (Opuntia species) is listed by the NIH Endotext as both an insulin sensitizer and carbohydrate absorption inhibitor studied in diabetes patients. Traditional use spans centuries in Mexican and Native American medicine. Clinical studies show significant reductions in blood glucose and insulin in T2DM patients consuming stems (nopales) or standardized extracts.

Colonic delivery of propionate at 10 g/day over 24 weeks prevented deterioration of insulin sensitivity in overweight adults in an RCT, associated with reduced circulating non-esterified fatty acids and improved pancreatic beta-cell FFAR2 signaling. A 7-week RCT also showed propionate decreased maximum insulin increments during glucose tolerance testing. However, dietary propionate at preservative doses acutely caused insulin resistance in a separate human RCT, indicating context-dependency.

Multiple RCTs and meta-analyses show psyllium significantly reduces the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), a validated marker of insulin sensitivity. A 2024 GRADE-assessed meta-analysis (19 RCTs, n=962) found a significant HOMA-IR reduction (WMD: −1.17; P<0.05). A double-blind RCT in women with PCOS also showed significant reductions in fasting insulin and HOMA1-IR and HOMA2-IR at 5 g twice daily for 8 weeks.

Specific P. marsupium phytochemicals—epicatechin, pterostilbene, marsupin, and pterosupin—have been shown to enhance insulin sensitivity in experimental models. Beta-cell regeneration by epicatechin further amplifies endogenous insulin production.

Pumpkin seed extract has demonstrated dose-dependent improvement in insulin sensitivity in diabetic animal models, operating through the PI3K/Akt signalling pathway in skeletal muscle. Polysaccharide fractions protect beta cells, while D-chiro-inositol (in C. ficifolia) acts as an insulin mediator. Preliminary human data exist, with larger trials needed.

RCT meta-analyses show purslane significantly reduces fasting blood glucose in type 2 diabetic populations, and a 2021 NAFLD RCT found significant reductions in insulin resistance (HOMA-IR). However, pooled meta-analytic data (16 RCTs) did not find significant effects on fasting insulin or HOMA-IR overall, suggesting the insulin-sensitizing effect may be context-dependent or modest.

Quercetin, a flavonoid found in onions, apples, and berries, improves insulin sensitivity in rodent models and shows AMPK activation. Human evidence includes a 17.5% improvement in HOMA-IR in women with PCOS (n=82) after 12 weeks at 1000 mg/day. It is a known AMPK activator alongside berberine, naringenin, and resveratrol.

A 1-year RCT in impaired glucose tolerance subjects showed quinoa significantly reduced the insulin resistance index (HOMA-IR) versus controls. A separate NAFLD RCT found improved HOMA-IR with quinoa grain substitution. Proposed mechanisms include polyphenol-mediated alpha-glucosidase inhibition, phytoecdysteroid-enhanced insulin signaling, and fiber-driven reduced postprandial glucose excursions.

Red raspberry polyphenols have demonstrated insulin-sensitizing actions in vitro and in animal models, with human clinical data showing significant attenuation of postprandial insulin responses. A 2025 crossover RCT found raspberry leaf tea co-ingested with sucrose reduced insulin concentrations by up to 161 pmol/L at 30 minutes. A 2019 crossover RCT in overweight/obese prediabetic adults found red raspberry intake attenuated postprandial insulin responses. The mechanisms include enzyme inhibition, reduced glucose absorption, and direct adipose tissue insulin sensitization.

Rehmannia extracts have been shown to improve insulin sensitivity in preclinical models. A 2022 Frontiers in Pharmacology study found RR extract reduced insulin sensitivity test values by ~14% in STZ-diabetic rats and increased glucose uptake by ~46% in HepG2 cells with insulin resistance. Catalpol lowers glucose in diabetic animal models and the Liuwei Dihuang pill reduced insulin resistance indices in a clinical study.

Catalpol and R. glutinosa polysaccharides improve insulin sensitivity in diabetic animal models, acting via AMPK activation, enhancement of insulin secretion from pancreatic islets, and reduction of insulin resistance markers. Clinical adjunct studies (Liuwei Dihuang + metformin) also show improved insulin-related indicators.

Animal studies demonstrate reishi polysaccharides improve insulin sensitivity by reducing hepatic glucose output, improving skeletal muscle glucose uptake, and acting as insulin secretagogues. The Cochrane review (2015) found inconsistent human evidence; the most recent human case report documented severe hypoglycaemia in a non-diabetic, confirming in vivo insulin-potentiating activity. MSKCC acknowledges 'mild antidiabetic effects' in clinical studies.

Resveratrol, a polyphenol from grape skin and red wine, activates SIRT1 and AMPK in skeletal muscle, improving insulin sensitivity by promoting GLUT4 translocation and glucose uptake. Multiple cell and animal studies confirm reversal of insulin resistance; human evidence shows metabolic benefits including improved mitochondrial capacity, though direct insulin sensitivity improvement in clinical trials is less consistent.

Chlorogenic acids and caffeine in robusta coffee act on pancreatic beta cells and peripheral insulin signalling pathways to support glucose homeostasis. In a Zucker rat model, robusta coffee reduced both fasting and postprandial insulin AUC. Epidemiological data show inverse associations between black coffee consumption and elevated HOMA-IR in women. CGA activates AMPK, a key insulin-sensitising kinase.

Multiple preclinical studies demonstrate rosmarinic acid improves insulin sensitivity in high-fat-diet and fructose-fed animal models, increasing GLUT4 expression in skeletal muscle, decreasing PEPCK expression in liver, and reducing HOMA-IR. These effects are dose-dependent and have been demonstrated in both type 1 and type 2 diabetic animal models.

A double-blind RCT in type 2 diabetes patients showed 500 mg/day rutin for 3 months improved HOMA-IR and QUICKI (established insulin sensitivity indices) compared to placebo. Preclinical data consistently show rutin improves insulin signaling and reduces insulin resistance in diabetic animal models.

Rye-based diets have shown improvements in insulin sensitivity in several RCTs, with mechanisms involving reduced postprandial insulinemia, SCFA-mediated signaling, and lower BCAA absorption. A 2017 RCT found rye bread with resistant starch increased insulin sensitivity (P<0.05) in healthy middle-aged subjects. The 2025 meta-analysis confirmed significant insulin AUC reduction across 31 RCTs.

In a 16-week crossover trial (n=35, obese post-menopausal diabetic women, 8 g/day), safflower oil improved insulin sensitivity and reduced trunk fat. A 12-week RCT in metabolic syndrome patients also showed improvement in insulin resistance. Safflower yellow in obese mice improved insulin sensitivity via the insulin signaling pathway and PGC1α.

Sage extract has been shown in clinical trials to improve markers of insulin sensitivity, including HbA1c and postprandial glucose, in type 2 diabetic patients. Animal studies confirm a rosiglitazone-like effect via PPARγ activation. Herbal reality sources document improved insulin sensitivity in diabetes, hyperlipidemia, and PCOS.

SDG improves insulin sensitivity in diet-induced obese mice by upregulating GLUT4 expression and enhancing the AKT phosphorylation cascade in muscle tissue. It also lowers fasting insulin and improves the HOMA-IR index. A human FLC RCT in type 2 diabetics showed reduced HbA1c and fasting glucose prior to multiple comparison correction.

Sesame consumption improves blood glucose and HbA1c levels across clinical trials, though effects on HOMA-IR (insulin resistance) are inconsistent. The 2022 meta-analysis (8 trials) found favorable effects on glucose but not on insulin resistance per se. Sesamin's interaction with SIRT1, PPARα, and Nrf2 pathways is proposed as the mechanistic basis for improved insulin signaling.

Silymarin has demonstrated statistically significant improvements in HOMA-IR and fasting insulin in multiple RCTs and a 2025 systematic review and meta-analysis covering 6 studies and 673 participants. A triple-blinded RCT found 25.9% reduction in HOMA-IR and a 6% increase in QUICKI. Effects are consistent across diabetic and non-diabetic obese populations.

RCT meta-analyses confirm soy protein supplementation significantly reduces HOMA-IR and fasting insulin in diabetic and metabolic syndrome populations. Animal studies show soy isoflavones improve insulin sensitivity by reducing visceral adiposity and decreasing inflammatory adipokines like TNF-α and resistin.

Soy isoflavones activate PPAR receptors and modulate insulin signaling pathways. RCT and meta-analytic evidence suggests modest improvements in HOMA-IR, particularly in women with PCOS or metabolic syndrome.

Clinical evidence, while mixed, suggests that soy protein and isoflavones can improve insulin sensitivity, particularly in postmenopausal women and those with metabolic syndrome. Soy isoflavones at doses ≥90 mg/day have been shown to reduce insulin levels in healthy postmenopausal women. The mechanism may involve PPAR pathway activation and improved lipid metabolism, with variability linked to individual equol-production status.

S. indicus is documented to improve insulin sensitivity through preclinical antidiabetic studies showing restored plasma insulin and hepatic glycogen. The Meratrim blend improves glucose parameters in obese humans. The phytopharmacological review (PMC) identifies antihyperglycemic as a scientifically evidenced activity.

Spinach thylakoids reduce postprandial insulin levels by slowing fat digestion and promoting satiety hormone release. Spinach extracts also contain compounds with insulin-like and insulin-sensitizing activity documented in preclinical models, with early supportive human data from GLP-1-mediated mechanisms.

A double-blind placebo-controlled RCT in 50 obese hypertensive patients found spirulina (2 g/day, 3 months) improved insulin sensitivity as assessed by euglycemic clamp, alongside lipid and antioxidant improvements. A 2025 systematic review confirmed spirulina enhances glycemic control and insulin sensitivity by increasing insulin production and reducing inflammatory mediators. AMPK activation and GLUT4-mediated glucose uptake are proposed mechanistic pathways.

Stevioside has demonstrated insulin-sensitizing effects in vitro, significantly increasing glucose uptake in insulin-resistant adipocytes (2.1–4.4 fold vs. control). Animal models show stevia extract enhances insulin sensitivity via mitochondrial function improvement and reduced oxidative stress in skeletal muscle. Human evidence is limited and mixed, with some trials showing no acute effect on the Matsuda insulin sensitivity index.

Preclinical and limited human-relevant data indicate steviol glycosides may improve insulin sensitivity through direct effects on insulin signaling pathways. Cell studies show stevioside increased glucose uptake up to 4.4-fold in insulin-resistant adipocytes. Mechanistic human metabolite research supports glucose-dependent insulinotropic activity.

Preclinical evidence from heat-killed S. thermophilus in a type 2 diabetic rat model shows significant reductions in HOMA-IR and fasting insulin levels alongside improved glycemic control. The mechanism proposed involves gut microbiota rebalancing and reduction of systemic inflammatory cytokines that impair insulin signaling.

In HFD-induced obese mice, succinic acid supplementation (40 mM) enhanced insulin sensitivity and improved glucose tolerance via PGC-1α/UCP1 adipose browning. A rat study using an oleic acid–succinic acid combination showed a 35.69% reduction in blood glucose levels. However, a separate mouse study found no effect on in vivo insulin tolerance, reflecting context-dependent results.

Multiple RCTs demonstrate sulforaphane improves insulin sensitivity and reduces HOMA-IR in type 2 diabetic patients. It activates PI3K/AKT and AMPK pathways and GLUT4 expression. The Axelsson 2017 Science Translational Medicine study is the landmark clinical trial.

Swertia chirayita improves insulin sensitivity through multiple mechanisms, with key compounds amarogentin and swertiamarin shown to modify glucose metabolism and insulin action in preclinical studies. Concentration-dependent insulin secretion stimulation from pancreatic β-cells has been demonstrated in vitro.

Taurine improves insulin signalling via the PI3K/Akt pathway and enhances pancreatic insulin secretion. Clinical RCTs and a 2025 meta-analysis confirm significant reductions in HOMA-IR and fasting insulin with taurine supplementation, though results vary by dose and population.

Administration of THIAA (META060) to HFD-fed obese and diabetic mice for 8 weeks normalized insulin sensitivity markers and reduced fasting hyperinsulinemia. A PMC review cites human evidence that THIAA-class compounds can restore insulin sensitivity in type II diabetes patients. THIAA may also act via PPARα/γ co-activation affecting adipocyte metabolism.

Epidemiological and metabolomic studies consistently show lower plasma TMG levels are associated with insulin resistance and higher type 2 diabetes risk. A 2017 study of nearly 2,400 people linked higher betaine and choline intake with reduced insulin resistance. An RCT in prediabetic adults found betaine reduced insulin AUC after oral glucose challenge. Direct improvement of insulin sensitivity by clamp method was not demonstrated in the same trial.

RCTs demonstrate that tocotrienol supplementation reduces HOMA-IR and fasting insulin in T2DM patients, indicating improved insulin sensitivity. The 24-week annatto delta-tocotrienol trial was the first to show direct tocotrienol effects on insulin resistance markers in humans.

Pterostilbene activates PI3K/Akt signaling in skeletal muscle and reduces HOMA-IR in fructose-fed diabetic rat models at 20–40 mg/kg/day. A PPAR-α agonist profile further supports improved lipid-mediated insulin sensitivity. Human-specific evidence for this endpoint is absent.

Tributyrin improved insulin sensitivity, glucose tolerance, and reduced fasting glucose in multiple rodent models of obesity and diabetes. The mechanism is partly GPR109A-dependent and involves reduced hepatic steatosis and adipose inflammation. No human RCTs on tributyrin for insulin sensitivity have been published.

Triphala enhances insulin sensitivity through PPARα/γ activation and β-cell modulation, with clinical evidence in type 2 diabetic patients showing reduced fasting blood glucose. The 2021 systematic review of 12 RCTs confirms glucose-lowering in diabetic but not normoglycemic subjects. Gallic and ellagic acids are key active constituents.

Meta-analytic evidence from multiple RCTs demonstrates curcumin significantly reduces HOMA-IR (insulin resistance index) and fasting serum insulin in metabolically dysregulated individuals. A meta-analysis of 17 RCTs found HOMA-IR reduced by −1.01 (p=0.0008) and fasting serum insulin by −1.69 mU/L. Curcumin has been shown to increase insulin sensitivity in liver, muscle, and adipose tissue in multiple models.

Clinical RCTs show CoQ10 supplementation improves markers of insulin sensitivity, including HOMA-IR, fasting insulin, and HbA1c, particularly in type 2 diabetes and PCOS populations. A 2024 umbrella review of meta-analyses found significant reductions in fasting blood glucose and HbA1c. Mechanisms include reduced oxidative-stress-driven impairment of insulin receptor signaling and improved adiponectin levels.

Vanadyl sulfate has been shown in several small human trials to improve both hepatic and peripheral insulin sensitivity in type 2 diabetes. The mechanism involves PTP1B inhibition and activation of serine/threonine kinases downstream of the insulin receptor. Results across studies are inconsistent and effect sizes are modest.

Vanadyl sulfate exhibits insulin-mimetic properties by activating insulin receptor tyrosine kinase and downstream signaling cascades. Multiple small clinical trials in T2DM patients report modest improvements in fasting blood glucose and insulin sensitivity. Animal studies confirm normalization of plasma glucose and HOMA-IR in diabetic models.

Whole-grain wheat and wheat arabinoxylan have been shown in RCTs to reduce peripheral insulin resistance. A randomized crossover trial in obese adults found whole-grain diets reduced peripheral insulin resistance and improved glucose kinetics. Wheat arabinoxylan concentrate significantly reduced postprandial insulin response in subjects with impaired glucose tolerance and metabolic syndrome.

Animal studies show wheatgrass reduces insulin resistance and raises insulin and C-peptide levels in diabetic models. The mechanisms involve antioxidant protection of pancreatic beta cells and modulation of glucose-metabolizing enzymes. No human RCT has specifically confirmed insulin sensitization.

Whey protein acutely enhances insulin secretion through incretin pathways, with meta-analytic evidence showing reduced HOMA-IR and fasting insulin in populations with metabolic syndrome. However, effects on long-term insulin sensitivity at the tissue level are more nuanced; some analyses in older adults show whey supplementation may raise fasting insulin. Mechanisms involve incretin-mediated β-cell stimulation and possible glutathione-driven improvements in redox-mediated insulin signaling.

XOS has been shown in pre-diabetic subjects and animal models to support insulin sensitivity via gut microbiota modulation, SCFA-mediated GLP-1 stimulation, and reduction of LPS-driven insulin resistance. A clinical pilot trial showed a non-significant trend to reduce 2-hour OGTT insulin in pre-diabetic subjects. Animal data with XOS in gestational diabetes and T2DM models show more robust improvements.

By inhibiting sucrase activity, D-xylose reduces postprandial glucose spikes, which in turn lowers the acute insulin demand placed on the pancreas. Human clinical data show lower insulin AUC following xylose-supplemented sucrose drinks. In vitro, D-xylose dose-dependently stimulated glucose uptake in skeletal muscle cells (C2C12), a key pathway in insulin-mediated glucose disposal.

Brewer's yeast improves insulin sensitivity in type 2 diabetic patients primarily via its chromium-containing glucose tolerance factor (GTF), which potentiates insulin receptor binding. RCT data (n=84, 12 weeks, 1,800 mg/day) show significant improvements in insulin sensitivity and insulin resistance markers alongside reductions in fasting blood glucose and HbA1c.

Human RCTs show yerba mate improves insulin sensitivity as measured by HOMA-IR and QUICKI indices, particularly in hypercholesterolemic and pre-diabetic individuals. Proposed mechanisms include hepatic insulin signaling modulation via TNF-α suppression and PI3K-AKT pathway interaction.

Zinc is essential for insulin synthesis, storage, secretion, and signal transduction at the insulin receptor. Multiple clinical trials and meta-analyses confirm zinc supplementation reduces fasting blood glucose, HbA1c, and HOMA-IR in T2DM and PCOS patients. A 2024 RCT combining gymnema, inositols, alpha-lactalbumin, and zinc demonstrated improved glycemic and lipid profiles in T2DM.

Preclinical rat studies show argan oil reduces insulin resistance via antioxidant and anti-inflammatory mechanisms. α-tocopherol in argan oil is proposed to improve insulin receptor signalling. No human clinical trials have specifically tested insulin sensitivity as a primary endpoint.

Animal studies consistently show beta-sitosterol improves insulin sensitivity markers including HOMA-IR, QUICKI, GLUT4 upregulation, and IRS-1/Akt signaling in multiple type-2 diabetic rodent models. No human RCTs have confirmed this effect.

Traditional use of huckleberry leaf preparations to support blood sugar and reduce insulin-related complaints aligns with the documented hypoglycemic folk applications within the Vaccinium genus. Scientific evidence from related species shows Vaccinium anthocyanins can reduce insulin resistance and enhance glucose uptake, but direct clinical data for huckleberry are lacking.

Opuntia streptacantha (nopal/prickly pear cactus) is a specific species widely used in Mexican traditional medicine for diabetes and blood sugar management. Clinical studies demonstrate significant reductions in blood glucose and insulin levels in T2DM patients consuming standardized preparations, supporting traditional use.

Tinospora cordifolia (Guduchi/Giloy) is an Ayurvedic medicinal plant with documented traditional use for diabetes management in India. Preclinical studies show insulin-sensitizing effects through PPAR-γ activation and improved glucose disposal; some clinical evidence suggests reductions in fasting blood glucose and HbA1c in T2DM patients.

Traditional Southeast Asian use of Tongkat Ali for diabetes management is documented in pharmacological reviews and the NIH LiverTox monograph. Animal studies demonstrate antihyperglycemic and glycolysis-assisting effects. Preclinical mechanistic data suggest potential improvement of insulin sensitivity via effects on pancreatic beta cells and glucose absorption. No dedicated human clinical trial measuring insulin sensitivity as a primary endpoint has been conducted.

MP seed extracts are proposed to act partly by increasing insulin secretion and reducing insulin resistance in animal models. Alpha-glucosidase inhibition slows glucose absorption. Animal studies show prevention of insulin resistance in high-fructose diet models. Evidence remains preclinical; no human insulin sensitivity trials have been conducted.

Traditional use in Iranian folk medicine and other systems for glycemic management, supported by preclinical evidence showing watercress extract enhances insulin secretion and reduces blood glucose in diabetic animal models. Human RCT evidence specifically targeting insulin sensitivity is absent.